Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiolabelled agents for PET imaging of tumor hypoxia.
Kurihara H, Honda N, Kono Y, Arai Y. Kurihara H, et al. Among authors: arai y. Curr Med Chem. 2012;19(20):3282-9. doi: 10.2174/092986712801215964. Curr Med Chem. 2012. PMID: 22664246 Review.
Transcriptome analysis of human oral squamous cancer SAS cells as an early response after boron neutron capture therapy.
Imamichi S, Ito T, Tong Y, Gao Z, Arai Y, Fujimori H, Chen L, Sanada Y, Nakamura S, Murakami Y, Ishiai M, Suzuki M, Itami J, Igaki H, Masunaga S, Masutani M. Imamichi S, et al. Among authors: arai y. Appl Radiat Isot. 2025 Jan 2;218:111648. doi: 10.1016/j.apradiso.2024.111648. Online ahead of print. Appl Radiat Isot. 2025. PMID: 39827644
Association between salt intake and blood pressure among community-dwelling older adults based on their physical frailty status.
Yoshida H, Kabayama M, Kido M, Godai K, Akagi Y, Li Y, Akasaka H, Takami Y, Yasumoto S, Ogawa M, Nakagawa T, Ikebe K, Arai Y, Masui Y, Hirata T, Gondo Y, Yamamoto K, Kamide K. Yoshida H, et al. Among authors: arai y. Hypertens Res. 2025 Jan 17. doi: 10.1038/s41440-024-02066-y. Online ahead of print. Hypertens Res. 2025. PMID: 39825114
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Sangro B, et al. Among authors: arai y. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8. Lancet. 2025. PMID: 39798579 Clinical Trial.
4,202 results